Advancements in Psoriasis Treatment: Moving Beyond Steroids towards Innovative Biologic Agents
Intractable dermatitis can cause cardiovascular disease if it worsens. The trend to develop treatments away from steroids and towards biologic agents “Spevigo” and “Skyrich” are attracting attention as second-generation psoriasis treatments after “Humira” and “Stelara” whose patents have expired. There is a great demand for oral treatments… Differentiation with TYK2 inhibitors ⓒGetty image bank [바이오타임즈] […]
Celltrion Healthcare Partners with CarePartners to Expand Uplyma Distribution in the US
Celltrion Healthcare Expands Distribution of Uplyma through CarePartners Specialty Pharmacies Celltrion Healthcare, a prominent specialty pharmacy chain in the US, has announced its partnership with CarePartners Pharmacy to distribute their flagship product, Uplyma. The adalimumab-containing drug will be exclusively available through CarePartners’ specialty pharmacies nationwide, starting at the end of this month. This collaboration ensures […]
AbbVie’s Skyrizi Emerges as Strong Competitor in the IBD Market, Threatening Existing Treatments
AbbVie’s Skyrizi (risankizumab) has demonstrated superiority over Stelara (ustekinumab) in a direct comparison study among patients with Crohn’s disease, raising hopes that Skyrizi will establish itself as a dominant force in the field of inflammatory bowel disease (IBD). The phase 3 clinical trial results of Skyrizi were announced by AbbVie, revealing a head-to-head comparison of […]
Celltrion Group Completes Merger with Celltrion Healthcare, Pursues Merger with Celltrion Pharmaceuticals
Celltrion Completes Merger, Pursues Further Expansion Celltrion Group Makes Major Leap in Global Pharma Industry Seoul, September 17th – Celltrion Group, a leading biotechnology company, has finalized its merger with Celltrion Healthcare and announced plans to pursue a merger with Celltrion Pharmaceuticals in the near future. This strategic move positions Celltrion as a global powerhouse […]
Samsung Bioepis Announces Successful Clinical Trial Results for Humira Biosimilar
Samsung Bioepis Achieves Primary Endpoints in Clinical Trial for Humira Biosimilar Samsung Bioepis, under the leadership of CEO Han-seung Ko, has announced the successful outcome of the Interchangeability (IC) clinical trial for their Humira biosimilar, known as SB5 or Hadrima in the US market. In a rigorous clinical trial conducted between August of last year […]
Drugs to be developed in virtual space… “I need to come up with an in silico strategy”
Prepare a forum for the exchange of views on patents, the core of the pharmaceutical industry, including strategies to protect the patent rights of ‘Humira’ and ‘Keytruda’, which compete for the main global pharmaceutical sales, and prepare a patent system for development drugs with digital and artificial intelligence (AI) technology in the future is done. […]
